Latest stories on INKT
MiNK Therapeutics, Inc. (INKT) files 8-K: Items 2.02, 9.01
SEC 8-K50 · neutralgeneral
MiNK Therapeutics (INKT) Q3 2026 Earnings Call Transcript
The Motley Fool64 · neutralearnings
MiNK outlines adaptive ARDS study up to 300 patients as ARPA-H commits up to $87M for BoSS program
Seeking Alpha64 · neutralproduct/pr
MiNK Therapeutics, Inc. (INKT) Q3 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Q3 2026 Mink Therapeutics Inc Earnings Call Transcript
GuruFocus50 · neutralearnings
MiNK Therapeutics reports Q3 EPS (50c), consensus (66c)
The Fly34 · bearishearnings
MiNK Therapeutics GAAP EPS of -$0.50 beats by $0.16, revenue of $0.2M beats by $0.13M
Seeking Alpha63 · neutralearnings
MiNK Therapeutics Q3 2026 Earnings Preview
Business Insider50 · neutralearnings
MiNK Therapeutics stock initiated at buy by H.C. Wainwright
Investing.com Analyst Ratings63 · neutralanalyst
MiNK Therapeutics assumed with a Buy at H.C. Wainwright
The Fly63 · neutralanalyst
MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
Business Insider52 · neutralearnings
MiNK Therapeutics price target raised to $50 from $43 at B. Riley
The Fly64 · neutralanalyst
MiNK Therapeutics management to meet virtually with B. Riley
The Fly56 · neutralgeneral
MiNK Therapeutics to present data on cancer research at SITC 2026
The Fly56 · neutralproduct/pr
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
Business Insider63 · neutralproduct/pr
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
GlobeNewswire73 · bullishproduct/pr
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
StockTitan67 · bullishproduct/pr